- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01459042
Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China
October 24, 2011 updated by: Wang Weiqing, Shanghai Jiao Tong University School of Medicine
Prevalence of Primary Aldosteronism and Status of Renin-Angiotensin System in Resistant Hypertension:An Observational Study in China
Recent studies indicate that primary aldosteronism (PA) is a much more common cause of hypertension than had been demonstrated historically.
In patients with resistant hypertension, the prevalence of PA from different clinics worldwide is about 10-20%.
As has been no such data in China, the investigators are conducting a PA study in different province of China to evaluate the prevalence of PA in patients with resistant hypertension.
Study Overview
Status
Completed
Study Type
Observational
Enrollment (Anticipated)
2000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Dep.endocrinology of Shanghai Ruijin Hospital, Shanghai Jiaotong university school of medcine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with resistant hypertension from different provinces of China
Description
Inclusion Criteria:
- patients with resistant hypertension
- age 18-65 years
Exclusion Criteria:
- known cause of hypertension
- heart failure
- renal dysfunction
- Stroke, transient ischaemic attack or myocardial infarction in the past 6 months
- cirrhosis
- pregnancy
- undertreatment of glucocorticoid
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
primary aldosteronism
|
essential hypertension
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Weiqing Wang, MD, PhD, Endocrinology Department of Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
October 1, 2011
Study Registration Dates
First Submitted
October 21, 2011
First Submitted That Met QC Criteria
October 24, 2011
First Posted (Estimate)
October 25, 2011
Study Record Updates
Last Update Posted (Estimate)
October 25, 2011
Last Update Submitted That Met QC Criteria
October 24, 2011
Last Verified
October 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19830409
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension, Resistant to Conventional Therapy
-
University of FloridaNational Heart, Lung, and Blood Institute (NHLBI); Emory UniversityNot yet recruitingHypertension, Resistant to Conventional TherapyUnited States
-
Memorial Health University Medical CenterUnknownHypertension, Resistant to Conventional TherapyUnited States
-
University of CambridgeBritish Heart FoundationUnknownHypertension, Resistant to Conventional TherapyUnited Kingdom
-
Cardiovascular Center FrankfurtCompletedHypertension, Resistant to Conventional TherapyGermany
-
Renal Dynamics GmbHBiosensors Europe SA; Physio-Logic Ltd. Israel; AmeRuss Clinical Trials LLC, USAUnknownHypertension Resistant to Conventional TherapyIsrael, Belgium, Germany, Hungary, Ireland, Poland, Russian Federation, Serbia
-
Macmillan Research Group UKNMP Medical Research InstituteCompletedHypertension, Resistant to Conventional TherapyIndia
-
CardiosonicUnknownHypertension, Resistant to Conventional TherapyAustralia
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloUnknownHypertension, Resistant to Conventional TherapyBrazil
-
MedispecHadassah Medical OrganizationUnknownHypertension, Resistant to Conventional TherapyIsrael
-
Mayo ClinicWithdrawnHypertension, Resistant to Conventional TherapyUnited States